Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.49 |
| ▸ | BCHE | P06276 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29329864 | 0.82 | ALDH1A1 (0.48) | ACHEALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL802630 | 0.76 | MAPT (0.48) | ALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL29853545 | 0.73 | MAPT (0.71) | ALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL8640666 | 0.72 | ACHE (0.42) | ACHEBCHE | |
| SCHEMBL3196920 | 0.70 | MAPT (0.56) | ALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL15292004 | 0.70 | MAPT (0.44) | ALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL24345877 | 0.69 | KMT2A (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL803071 | 0.69 | AKR1B1 (0.43) | ALDH1A1SMN1; SMN2ROCK2MAPT | |
| SCHEMBL16494147 | 0.68 | ACHE (0.51) | ACHEBCHEALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL805440 | 0.68 | MAOB (0.45) | ACHEBCHEALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239762-A1 | NOVEL HETEROCYCLIC COMPOUNDS | FLORATEK PHARMA S A (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240239762-A1 | NOVEL HETEROCYCLIC COMPOUNDS | FLORATEK PHARMA S A (CH) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239762-A1 | NOVEL HETEROCYCLIC COMPOUNDS | UGT1A1, SLC10A1, CYP11B1 | ACHE 1079/4885BCHE 1073/4885ALDH1A1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.